Tag Archives: type 2 diabetes

Coffee consumption shows CHD benefits in women A meta-analysis of a number of cohorts studies published in the International Journal of Cardiology (2009;137:216-25) demonstrates that habitual coffee consumption may be associated with a lower risk of coronary heart disease (CHD) in women. Analysis of data from 21 cohort studies showed that moderate coffee consumption (of up to four cups of coffee per day) were associated with a 18% reduction in risk of CHD in women.  The investigators note that such an effect was unlikely to be caused by chance. Further benefits have been shown from a meta-analysis published in the Archives of Internal Medici

In one study, a group led by Dr Andre Pascal Kengne (University of Sydney, Australia), noted that data from the recent ADVANCE (Action in Diabetes and Vascular Disease) trial conducted in more than 7,000 patients with diabetes worldwide, suggested that the UKPDS equation overestimated risk of major coronary heart disease (CHD) by 198%, and the two Framingham equations overestimated the risk by 146% and 289%. A group from Greece led by Dr Athanasios Kofinis (National University of Athens) reported similar findings from a five-year study of more than 900 people with diabetes.

Summary of therapies and key recommendations are: Insulin therapy (including the long-acting insulin analogues, insulin detemir, insulin glargine) Insulin detemir and insulin glargine, like NPH insulin, provide slowly-released insulin to meet basal requirements.  When the decision to start insulin is made, human NPH insulin should be started; healthcare professionals should consider switching to a long-acting insulin analogue if the patient experiences significant hypoglycaemia, is unable to use the device needed to inject NPH insulin, or needs help to inject the insulin from a carer or healthcare professional, and for whom switching to a lo

DIRECT results suggest increased regression of retinopathy in type 2 diabetes Three studies of the effect of candesartan on diabetic retinopathy produced mixed results in the first large-scale programme assessing the effect of an angiotensin receptor blocker on the incidence and progression of eye complications in patients with diabetes. The primary end points in the three DIabetic REtinopathy Candesartan Trials (DIRECT) were just missed. But investigators and independent clinicians argued the data were strong enough to influence clinical practice in secondary care although were insufficient to support a licence change. Professor Anthony Barn

No content available

No content available

No content available

No content available

No content available

No content available